{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(4)"],"submitter":["Nickols NG"],"pubmed_abstract":["<h4>Importance</h4>SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2.<h4>Objective</h4>To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19.<h4>Design, setting, and participants</h4>The Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) phase 2, placebo-controlled, double-blind, randomized clinical trial compared efficacy of degarelix plus standard care vs placebo plus standard care on clinical outcomes in men hospitalized with COVID-19 but not requiring invasive mechanical ventilation. Inpatients were enrolled at 14 Department of Veterans Affairs hospitals from July 22, 2020, to April 8, 2021. Dat"],"journal":["JAMA network open"],"pagination":["e227852"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9020208"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial."],"pmcid":["PMC9020208"],"pubmed_authors":["Wong YN","Bedimo RJ","Aguayo SM","Goetz MB","Soo Hoo G","Mirsaeidi MS","Villareal RC","Muthiah MP","Clise CE","Huggins JT","Belligund PM","Mi Z","Schoen MW","Adorno Febles V","Rettig MB","Biswas K","Orshansky G","Ghayouri L","Al-Ajam M","Geelhoed M","Tsai S","Maraka S","Montgomery RB","Robinson KW","DeMatt E","Levin ER","Becker DJ","Ambrogini E","Graber CJ","Tran S","Nickols NG","Bhattacharya D","Makarov DV","Norman LE"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.","description":"<h4>Importance</h4>SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2.<h4>Objective</h4>To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19.<h4>Design, setting, and participants</h4>The Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) phase 2, placebo-controlled, double-blind, randomized clinical trial compared efficacy of degarelix plus standard care vs placebo plus standard care on clinical outcomes in men hospitalized with COVID-19 but not requiring invasive mechanical ventilation. Inpatients were enrolled at 14 Department of Veterans Affairs hospitals from July 22, 2020, to April 8, 2021. Dat","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-31T01:07:34.833Z","creation":"2025-04-04T11:31:36.789Z"},"accession":"S-EPMC9020208","cross_references":{"pubmed":["35438754"],"doi":["10.1001/jamanetworkopen.2022.7852"]}}